Drugs / JWCAR201
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06567080 | Sep 2024 → Sep 2025 overdue | large B-cell lymphoma, systemic lupus erythematosus | RenJi Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06517004 | Jul 2024 → Dec 2025 overdue | diffuse large B-cell lymphoma | Fudan University | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-05-09 | Shanghai JW Therapeutics Co., Ltd. | Results ASGCT 2026 | JW Therapeutics Presents Preclinical Data of JWCAR201 and JWCAR239 at the 29th Annual Meeting of the American Society of Gene & Cell Therapy jwtherapeutics.com ↗
Compared with anti-CD19 CAR-T cells, JWCAR201 displayed significantly enhanced cytotoxicity against diverse antigen-positive target cells in vitro. |
| 2025-12-08 | Shanghai JW Therapeutics Co., Ltd. | Results JW Therapeutics Presents JWCAR201 IIT Study Data at the 67th American Society of Hematology Annual Meeting jwtherapeutics.com ↗
As of October 30, 2025, seven enrolled subjects in this study have completed JWCAR201 infusion, and preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) studies have been completed across the three dose groups. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-09 | Shanghai JW Therapeutics Co., Ltd. | ASGCT 2026 | JW Therapeutics Presents Preclinical Data of JWCAR201 and JWCAR239 at the 29th Annual Meeting of the American Society of Gene & Cell Therapy jwtherapeutics.com ↗ |
| 2025-12-08 | Shanghai JW Therapeutics Co., Ltd. | JW Therapeutics Presents JWCAR201 IIT Study Data at the 67th American Society of Hematology Annual Meeting jwtherapeutics.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JWCAR201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06567080 ↗ |
| Modality | Cell therapy | “Autologous CD19/CD20-directed CAR-T cells” NCT06517004 ↗ |
| Route | Intravenous | “single infusion intravenously” NCT06517004 ↗ |
| Target | CD19 | “Autologous CD19/CD20-directed CAR-T cells” NCT06517004 ↗ |